In this Q&A we discuss the role of PARP inhibitors in cancer treatment, their role in triple-negative breast cancer patients and look forward to ongoing trials in this setting.
Judy Garber, MD, MPH
Advertisement
Articles by Judy Garber, MD, MPH
Advertisement
Latest Updated Articles
Judy Garber on PARP Inhibitors for Triple-Negative Breast CancerNovember 15th 2017
Advertisement
Advertisement
Trending on CancerNetwork
1
Atirmociclib/Fulvestrant Improves PFS in HR+/HER2– Breast Cancer
2
FDA Approves Companion Diagnostic for Niraparib in Advanced Ovarian Cancer
3
Which Novel Drug Classes Hold Promise in Multiple Myeloma Therapy?
4
Investigators to Discontinue Trial of Eftilagimod Alfa in Frontline NSCLC
5